샘플 요청 목록

 카트 문의
시장보고서
상품코드
1575043

톡소플라스마증 치료 시장 : 유형별, 투여 경로별, 약물 종류별, 유통 채널별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율, 예측(2024-2032년)

Toxoplasmosis Treatment Market, By Type, By Route of Administration, By Drug Class, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
발행일: | 리서치사: AnalystView Market Insights | 페이지 정보: 영문 260 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

톡소플라스마증 치료 시장 규모는 2023년 31억 9,032만 달러로 2024년부터 2032년까지 연평균 6.60%의 성장률을 기록할 것으로 예상됩니다.

질병에 대한 인식 증가, 취약 계층의 유병률 증가, 약물 개발의 발전이 이 시장을 주도하고 있습니다. 또한, 보다 효과적이고 표적화된 치료법에 대한 연구가 진행되고 있는 것도 시장의 향후 전망을 형성할 것으로 예상됩니다. 전반적으로 톡소플라스마증 치료 시장은 특히 발병률이 높은 지역에서 공중보건에 중요한 역할을 하고 있습니다.

톡소플라스마증 치료 시장 - 시장 역학

태아의 발달에 대한 잠재적 합병증에 대한 이해도 증가

임신 중 톡소플라스마증으로 인한 잠재적 합병증에 대한 인식이 높아지면서 톡소플라스마증 치료 시장의 중요한 촉진제가 되고 있습니다. 톡소플라스마증은 기생충 톡소플라즈마 곤디(Toxoplasma gondii)에 의해 발생하며, 신경학적 문제, 발달 지연 등 태아에게 심각한 문제를 일으킬 수 있습니다. 미국 질병예방통제센터(CDC)에 따르면, 미국에서는 매년 약 400명에서 4,000명의 유아가 선천성 톡소플라스마증으로 태어나며, 이 중 10-15%는 심각한 건강 합병증에 직면할 수 있다고 합니다. 이러한 이해도가 높아짐에 따라 의료진은 임산부에게 정기적인 검진을 권장하고 있으며, 검사 및 효과적인 치료법에 대한 수요가 증가하고 있습니다. 이에 따라 제약회사들은 혁신적인 치료법과 예방법 개발에 더욱 박차를 가하고 있으며, 이러한 시급한 건강 문제에 대한 시장 확대에 박차를 가하고 있습니다.

톡소플라스마증 치료 시장 - 주요 인사이트

당사의 리서치 애널리스트의 분석에 따르면, 세계 시장은 예측 기간(2024-2032년) 동안 연평균 약 6.60%의 CAGR로 성장할 것으로 예상됩니다.

유형별 세분화에서는 선천성 톡소플라스마증이 2023년 가장 큰 시장 점유율을 차지할 것으로 예측됐습니다.

투여 경로를 세분화하면 2023년에는 경구제가 주요 유형으로 나타났습니다.

약물 종류별로는 2023년 피리메타민이 주요 유형으로 나타났습니다.

지역별로는 북미가 2023년 매출 1위를 차지했습니다.

톡소플라스마증 치료 시장 - 세분화 분석:

세계 톡소플라스마증 치료 시장은 유형, 투여 경로, 약물 종류, 유통 채널 및 지역에 따라 세분화됩니다.

시장은 유형별로 후천성 톡소플라스마증과 선천성 톡소플라스마증의 두 가지로 나뉩니다. 선천성 톡소플라즈마 증은 가장 중요한 부문입니다. 선천성 톡소플라스마증이 가장 중요한 분야인 이유는 신생아에 대한 심각한 건강 영향과 조기 발견 및 개입에 대한 의료진의 인식이 높아졌기 때문입니다. 선천성 톡소플라스마증은 심각한 신경학적 합병증과 안과적 합병증을 유발할 수 있어 효과적인 치료가 필수적입니다. 임신 중 모체 감염률이 증가함에 따라 표적 치료 및 예방 조치의 필요성이 더욱 강조되고 있습니다. 그 결과, 이 취약한 집단에 대한 치료 옵션 개선에 초점을 맞춘 연구 개발에 많은 투자가 이루어지고 있습니다.

약물 종류에 따라 시장은 피리메타민, 스피라마이신, 류코볼린, 설파디아진, 엽산, 기타 등 5가지 범주로 나뉩니다. 피리 메타 민은 가장 중요한 약물 클래스입니다. 피리메타민은 급성 및 만성 톡소플라스마증, 특히 면역 결핍 환자 및 심각한 증상을 가진 환자의 1차 치료제로서 효과가 있어 주목받고 있습니다. 피리메타민은 기생충 양을 감소시키는 능력이 있고, 병용요법에서의 사용도 확립되어 있어 임상현장에서 그 중요성이 커지고 있습니다. 또한, 복용량을 최적화하고 부작용을 최소화하기 위한 지속적인 연구를 통해 치료 프로토콜에서 피리메타민의 우월성이 강화되어 톡소플라스마증 치료의 핵심이 되고 있습니다.

톡소플라스마증 치료 시장 - 지리적 인사이트

톡소플라스마증 치료 시장에서 가장 큰 지역은 북미 지역입니다. 이 지역은 기후와 반려동물 사육 등의 요인으로 인해 환자 수가 많은 지역입니다. 또한 질병에 대한 인식이 높아지고 의료 시스템이 개선되면서 시장 성장에 힘을 보태고 있습니다. 많은 기업들이 환자를 구하기 위해 새로운 치료법과 약물을 개발하고 있습니다.

이 지역의 연구 개발은 활발히 진행되고 있으며, 보다 효과적인 대안을 창출하고 있습니다. 의료 서비스 제공자와 제약 회사의 파트너십은 치료의 효과를 높이고 있습니다. 전반적으로 북미는 톡소플라스마증 치료 시장 성장에 중요한 역할을 하고 있습니다.

톡소플라스마증 치료 시장 - 경쟁 상황:

톡소플라스마증 치료 시장의 경쟁 구도는 Roche, Sanofi, Pfizer와 같은 대형 제약회사와 혁신적인 생명공학 기업들이 주도하고 있습니다. 현재 치료법은 주로 피리메타민과 설파디아진 또는 클린다마이신의 병용요법이지만, 약제 내성을 해결하고 효능을 향상시키기 위한 새로운 치료법의 연구개발에 중점을 두고 있습니다. 지역별로는 북미와 유럽에서 두드러진 성장세를 보이고 있으며, 이는 인지도 향상과 의료 서비스 접근성 향상에 힘입어 신흥 시장에서도 새로운 기회를 창출하고 있습니다.

학계와의 공동연구와 합작투자가 R&D 역량을 강화하는 한편, 규제 당국의 승인 절차는 여전히 중요한 요소로 작용하고 있습니다. 시장 트렌드는 맞춤형 의료와 첨단 치료제로 향하고 있으며, 각 회사는 제품 차별화와 경쟁력 있는 가격 책정에 중점을 둔 전략을 채택하고 있습니다. 이러한 상황은 역동적이며, 기술 혁신과 진화하는 도전 과제를 극복해야 하는 역동적인 상황입니다.

목차

제1장 톡소플라스마증 치료 시장 개요

  • 조사 범위
  • 시장 추정 연도

제2장 주요 요약

  • 시장 내역
  • 경쟁 인사이트

제3장 톡소플라스마증 치료의 주요 시장 동향

  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
  • 시장 전망 동향

제4장 톡소플라스마증 치료 산업 연구

  • PEST 분석
  • Porter's Five Forces 분석
  • 성장 전망 매핑
  • 규제 프레임워크 분석

제5장 톡소플라스마증 치료 시장 : COVID-19의 영향 분석

  • COVID-19 이전의 영향 분석
  • COVID-19 이후의 영향 분석

제6장 톡소플라스마증 치료 시장 상황

  • 톡소플라스마증 치료 시장 점유율 분석, 2023년
  • 내역 데이터 : 주요 제조업체별
    • 기존 기업 분석
    • 신흥 기업 분석

제7장 톡소플라스마증 치료 시장 - 유형별

  • 개요
    • 부문 점유율 분석 : 유형별
    • 후천성 톡소플라스마증
    • 선천성 톡소플라스마증

제8장 톡소플라스마증 치료 시장 - 투여 경로별

  • 개요
    • 부문 점유율 분석 : 투여 경로별
    • 비경구
    • 경구

제9장 톡소플라스마증 치료 시장 - 약물 종류별

  • 개요
    • 부문 점유율 분석 : 약물 종류별
    • 피리메타민
    • 스피라마이신
    • 류코보린
    • 설파디아진
    • 엽산
    • 기타

제10장 톡소플라스마증 치료 시장 - 유통 채널별

  • 개요
    • 부문 점유율 분석 : 유통 채널별
    • 병원 약국
    • 소매 약국
    • 온라인 약국

제11장 톡소플라스마증 치료 시장 - 지역별

  • 소개
  • 북미
    • 개요
    • 북미의 주요 제조업체
    • 미국
    • 캐나다
  • 유럽
    • 개요
    • 유럽의 주요 제조업체
    • 독일
    • 이탈리아
    • 영국
    • 프랑스
    • 러시아
    • 네덜란드
    • 스웨덴
    • 폴란드
    • 기타
  • 아시아태평양(APAC)
    • 개요
    • 아시아태평양의 주요 제조업체
    • 인도
    • 중국
    • 일본
    • 한국
    • 호주
    • 태국
    • 인도네시아
    • 필리핀
    • 기타
  • 라틴아메리카
    • 개요
    • 라틴아메리카의 주요 제조업체
    • 브라질
    • 멕시코
    • 아르헨티나
    • 콜롬비아
    • 기타
  • 중동 및 아프리카
    • 개요
    • 중동 및 아프리카의 주요 제조업체
    • 사우디아라비아
    • 아랍에미리트
    • 이스라엘
    • 터키
    • 알제리
    • 이집트
    • 기타

제12장 주요 벤더 분석 - 톡소플라스마증 치료 업계

  • 경쟁 대시보드
  • 기업 개요
    • Roche
    • Sanofi
    • Pfizer
    • Novartis
    • GlaxoSmithKline
    • Bristol-Myers Squibb
    • AbbVie
    • Merck & Co.
    • Teva Pharmaceutical Industries
    • AstraZeneca
    • Gilead Sciences
    • Eisai Co., Ltd.
    • Lundbeck
    • Boehringer Ingelheim
    • Hoffmann - La Roche
    • Amgen

제13장 애널리스트의 전방위 전망

ksm 24.11.15

REPORT HIGHLIGHT

The Toxoplasmosis Treatment Market size was valued at USD 3,190.32 million in 2023, expanding at a CAGR of 6.60% from 2024 to 2032.

The toxoplasmosis treatment market encompasses a range of pharmaceutical products and therapies to manage infections caused by the parasite Toxoplasma gondii. This condition primarily affects immunocompromised individuals, pregnant women, and those with weakened immune systems, making effective treatment critical. Key medications include pyrimethamine, sulfadiazine, and clindamycin, often used in combination to enhance efficacy.

The market is driven by rising awareness of the disease, increasing prevalence in vulnerable populations, and advancements in drug development. Additionally, ongoing research into more effective and targeted therapies is expected to shape the future landscape of the market. Overall, the toxoplasmosis treatment market plays a vital role in public health, particularly in regions with high incidence rates.

Toxoplasmosis Treatment Market- Market Dynamics

Increased understanding of potential complications for fetal development.

The increasing awareness of the potential complications from toxoplasmosis during pregnancy has become a significant driver for the toxoplasmosis treatment market. Toxoplasmosis, caused by the parasite Toxoplasma gondii, can lead to severe issues in unborn children, including neurological problems and developmental delays. According to the Centers for Disease Control and Prevention (CDC), around 400 to 4,000 infants are born annually in the U.S. with congenital toxoplasmosis, with 10% to 15% potentially facing serious health complications. This growing understanding prompts healthcare providers to recommend routine screening for pregnant women, thereby elevating the demand for both testing and effective treatments. As a result, pharmaceutical companies are increasingly motivated to develop innovative therapies and preventive measures, fostering market expansion in response to these pressing health concerns.

Toxoplasmosis Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 6.60% over the forecast period (2024-2032)

Based on Type segmentation, Congenital Toxoplasmosis was predicted to show maximum market share in the year 2023

Based on Route of Administration segmentation, oral was the leading type in 2023

Based on Drug Class segmentation, Pyrimethamine was the leading type in 2023

Based on region, North America was the leading revenue generator in 2023

Toxoplasmosis Treatment Market- Segmentation Analysis:

The Global Toxoplasmosis Treatment Market is segmented based on Type, Route of Administration, Drug Class, Distribution Channel, and Region.

The market is divided into two categories based on Type: Acquired Toxoplasmosis and congenital Toxoplasmosis. Congenital Toxoplasmosis is the most significant segment. This prominence arises from the critical health implications for newborns and the heightened awareness among healthcare providers regarding early detection and intervention. Congenital infections can lead to severe neurological and ocular complications, making effective treatment vital. The increasing incidence of maternal infection during pregnancy further emphasizes the need for targeted therapies and preventative measures. As a result, there is substantial investment in research and development focused on improving treatment options for this vulnerable population.

The market is divided into five categories based on Drug Class: Pyrimethamine, Spiramycin, Leucovorin, Sulfadiazine, Folic Acid, and Others. Pyrimethamine is the most significant drug class. Its prominence stems from its effectiveness as a primary treatment for both acute and chronic toxoplasmosis, particularly in immunocompromised patients and those with severe symptoms. Pyrimethamine's ability to reduce the parasite load and its established use in combination therapies enhance its importance in clinical practice. Additionally, the ongoing research into optimizing its dosage and minimizing side effects continues to reinforce its dominant position in treatment protocols, making it a cornerstone in managing Toxoplasmosis.

Toxoplasmosis Treatment Market- Geographical Insights

The largest region in the toxoplasmosis treatment market is North America. This area has a high number of cases due to factors like climate and pet ownership. The growing awareness of the disease and better healthcare systems also boost the market. Many companies are developing new treatments and drugs to help patients.

Research and development in this region are strong, leading to more effective options. Partnerships between healthcare providers and pharmaceutical companies enhance treatment availability. Overall, North America plays a key role in the growth of the toxoplasmosis treatment market.

Toxoplasmosis Treatment Market- Competitive Landscape:

The Toxoplasmosis treatment market features a competitive landscape dominated by major pharmaceutical companies like Roche, Sanofi, and Pfizer, alongside innovative biotech firms. Current treatment options primarily include pyrimethamine combined with sulfadiazine or clindamycin, there is a growing emphasis on research and development for novel therapies to address drug resistance and improve efficacy. Geographic growth is notable in North America and Europe, driven by increased awareness and healthcare access, with emerging markets presenting additional opportunities.

Collaborative efforts with academic institutions and joint ventures enhance R&D capabilities, while regulatory approval processes remain crucial. The market trends towards personalized medicine and advanced therapeutics, prompting companies to adopt strategies focusing on product differentiation and competitive pricing. The landscape is dynamic, characterized by innovation and a need to navigate evolving challenges.

Recent Developments:

In April 2023, Computational screening of FDA-approved drugs aims to identify potential inhibitors of Toxoplasma gondii proteins like TgDHFR, TgPRS, and TgCDPK1 through molecular docking, stability assessments, and ADMET analysis, followed by in vitro validation of promising candidates.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL TOXOPLASMOSIS TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Roche
  • Sanofi
  • Pfizer
  • Novartis
  • GlaxoSmithKline
  • Bristol-Myers Squibb
  • AbbVie
  • Merck & Co.
  • Teva Pharmaceutical Industries
  • AstraZeneca
  • Gilead Sciences
  • Eisai Co., Ltd.
  • Lundbeck
  • Boehringer Ingelheim
  • Hoffmann-La Roche
  • Amgen

GLOBAL TOXOPLASMOSIS TREATMENT MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Acquired Toxoplasmosis
  • Congenital Toxoplasmosis

GLOBAL TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Parenteral
  • Oral

GLOBAL TOXOPLASMOSIS TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Pyrimethamine
  • Spiramycin
  • Leucovorin
  • Sulfadiazine
  • Folic Acid
  • Other

GLOBAL TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL TOXOPLASMOSIS TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Toxoplasmosis Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Toxoplasmosis Treatment Market Snippet by Type
    • 2.1.2. Toxoplasmosis Treatment Market Snippet by Route of Administration
    • 2.1.3. Toxoplasmosis Treatment Market Snippet by Drug Class
    • 2.1.4. Toxoplasmosis Treatment Market Snippet by Distribution Channel
    • 2.1.5. Toxoplasmosis Treatment Market Snippet by Country
    • 2.1.6. Toxoplasmosis Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Toxoplasmosis Treatment Key Market Trends

  • 3.1. Toxoplasmosis Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Toxoplasmosis Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Toxoplasmosis Treatment Market Opportunities
  • 3.4. Toxoplasmosis Treatment Market Future Trends

4. Toxoplasmosis Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Toxoplasmosis Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Toxoplasmosis Treatment Market Landscape

  • 6.1. Toxoplasmosis Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Toxoplasmosis Treatment Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2023 & 2032 (%)
    • 7.1.2. Acquired Toxoplasmosis
    • 7.1.3. Congenital Toxoplasmosis

8. Toxoplasmosis Treatment Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 8.1.2. Parenteral
    • 8.1.3. Oral

9. Toxoplasmosis Treatment Market - By Drug Class

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
    • 9.1.2. Pyrimethamine
    • 9.1.3. Spiramycin
    • 9.1.4. Leucovorin
    • 9.1.5. Sulfadiazine
    • 9.1.6. Folic Acid
    • 9.1.7. Other

10. Toxoplasmosis Treatment Market - By Distribution Channel

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 10.1.2. Hospital Pharmacies
    • 10.1.3. Retail Pharmacies
    • 10.1.4. Online Pharmacies

11. Toxoplasmosis Treatment Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Toxoplasmosis Treatment Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Toxoplasmosis Treatment Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Toxoplasmosis Treatment Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Toxoplasmosis Treatment Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Toxoplasmosis Treatment Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Toxoplasmosis Treatment Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. Roche
    • 12.2.2. Sanofi
    • 12.2.3. Pfizer
    • 12.2.4. Novartis
    • 12.2.5. GlaxoSmithKline
    • 12.2.6. Bristol-Myers Squibb
    • 12.2.7. AbbVie
    • 12.2.8. Merck & Co.
    • 12.2.9. Teva Pharmaceutical Industries
    • 12.2.10. AstraZeneca
    • 12.2.11. Gilead Sciences
    • 12.2.12. Eisai Co., Ltd.
    • 12.2.13. Lundbeck
    • 12.2.14. Boehringer Ingelheim
    • 12.2.15. Hoffmann-La Roche
    • 12.2.16. Amgen

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제